Neurizon Therapeutics has secured registered trademark protection for NEURIZON across all major global commercial markets, cementing its brand as it advances toward late-stage clinical development.

 

The clinical-stage biotechnology company confirmed trademark registrations are now complete in the United States, European Union, United Kingdom, Australia and Japan — jurisdictions that collectively represent the world’s most significant pharmaceutical markets.

 

The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions, enabling consistent global deployment as the company expands its international footprint.

 

All trademarks cover Class 42 services, including pharmaceutical research and development, clinical trial services and neurological therapeutics R&D. The scope directly supports Neurizon’s current clinical activities and its lead program, NUZ-001, which is underpinned by a growing global patent portfolio.

 

The milestone strengthens Neurizon’s broader intellectual property strategy, which already includes granted and pending patents for NUZ-001 in key markets, and signals the company’s continued evolution into a globally positioned biotechnology developer.

 

Completion of the US trademark is particularly strategic, with the United States identified as Neurizon’s primary long-term value and commercialisation market. The registration establishes a solid platform for future US-based operations, including clinical trial partnerships, strategic collaborations, licensing discussions and third-party service engagements as the company progresses toward later-stage development.

 

Neurizon has progressively rolled out registered trademark usage across its external communications throughout 2025, ensuring compliance and brand consistency while finalising its international registration suite.

 

Managing Director and Chief Executive Officer Dr Michael Thurn said: “Securing global trademark protection for NEURIZON strengthens the Company’s intellectual property framework and supports consistent global brand deployment across key pharmaceutical markets. 

 

"Together with our patent portfolio, this provides Neurizon with greater flexibility as we advance NUZ-001, including optionality should the Company elect to pursue commercialisation independently or in partnership.”